Among those currently scheduled to release results next week:
09-Sep | |
|---|---|
Half Year Results |
10-Sep |
|---|
No FTSE 350 Reporters |
From market news and analysis to expert insights, access it all on the go with our award-winning app.
11-Sep | |
|---|---|
Full Year Results | |
Half Year Results | |
Half Year Results |
12-Sep | |
|---|---|
Half Year Results | |
Q1 Trading Statement | |
Full Year Results | |
Full Year Results | |
Half Year Results | |
Half Year Trading Statement |
13-Sep |
|---|
No FTSE 350 Reporters |
Can Fevertree keep full-year guidance on track?
Last we heard, Fevertree had been scooping up market share across its regions which had helped to increase sales. Innovation across Rum, Vodka and other spirits has helped boost the group’s leading position in the UK, and growth in Europe continues to grow ahead of the broader mixer category.
Fevertree’s already said it’s comfortable with full-year expectations, which at the time of the last update in June pointed towards 8% sales growth and underlying cash profit margins of around 15%. We’ll be keeping a close eye on whether these targets are still on track when half-year results are announced next week, with market forecasts currently suggesting this could be a slight stretch.
Unless otherwise stated estimates are a consensus of analyst forecasts provided by Refinitiv. These estimates are not a reliable indicator of future performance. Past performance is not a guide to the future. Investments rise and fall in value so investors could make a loss.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.